Synergy Pharmaceuticals

Synergy Pharmaceuticals Inc. (Synergy) is a biopharmaceutical company focused on the development and commercialization of gastrointestinal (GI) therapies. The Company's GI platform includes two lead product candidates: plecanatide and dolcanatide. It is engaged in the discovery, research and development involving uroguanylin analogs for the treatment of functional GI disorders and inflammatory bowel disease. Plecanatide is the Company's uroguanylin analog being evaluated for use as a once-daily tablet for two functional GI disorders, chronic idiopathic constipation (CIC) and irritable bowel syndrome with constipation (IBS-C). Plecanatide is a 16-amino acid peptide that is structurally identical to uroguanylin with the exception of a single amino acid change. Dolcanatide is also its uroguanylin analog being explored for inflammatory bowel disease (IBD). Dolcanatide is designed to be an analog of uroguanylin with resistance to standard digestive breakdown by proteases in the intestine.
Type
Public
HQ
New York, US
Employees
44 (est)
Synergy Pharmaceuticals is headquartered in New York, US

Synergy Pharmaceuticals Locations

New York, US

Synergy Pharmaceuticals Metrics

Synergy Pharmaceuticals Summary

Market capitalization

$986 M

Closing share price

$5.61
Synergy Pharmaceuticals's latest market capitalization is $986 M.

Synergy Pharmaceuticals Market Value History

33% of current employees of Synergy Pharmaceuticals are female and 67% are male.

Synergy Pharmaceuticals News

Synergy Pharmaceuticals Company Life

You may also be interested in